EMEA-001877-PIP01-15-M04 - paediatric investigation plan

fremanezumab

Key facts

• Invented name:
  Ajovy
• Active Substance:
  fremanezumab
• Therapeutic area:
  Neurology
• Decision number:
  P/0378/2023
• PIP number:
  EMEA-001877-PIP01-15-M04
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Prevention of migraine headaches
• Route(s) of administration:
  Subcutaneous use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  08/09/2023

Decision

P/0378/2023 : EMA decision of 8 September 2023 on the acceptance of a modification of an agreed paediatric investigation plan for fremanezumab (Ajovy), (EMEA-001877-PIP01-15-M04)

Reference Number: EMA/351214/2023